TLR agonists promote formation of Tertiary Lymphoid Structure and improve anti-glioma immunity.

IF 16.4 1区 医学 Q1 CLINICAL NEUROLOGY Neuro-oncology Pub Date : 2024-08-27 DOI:10.1093/neuonc/noae167
Shaoping Shen, Yong Cui, Mingxiao Li, Kefu Yu, Qinghui Zhu, Xiaokang Zhang, Weicheng Shen, Haoyi Li, Haihui Jiang, Ming Li, Xijie Wang, Xuzhe Zhao, Xiaohui Ren, Song Lin
{"title":"TLR agonists promote formation of Tertiary Lymphoid Structure and improve anti-glioma immunity.","authors":"Shaoping Shen, Yong Cui, Mingxiao Li, Kefu Yu, Qinghui Zhu, Xiaokang Zhang, Weicheng Shen, Haoyi Li, Haihui Jiang, Ming Li, Xijie Wang, Xuzhe Zhao, Xiaohui Ren, Song Lin","doi":"10.1093/neuonc/noae167","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Glioma, characterized by limited lymphocytic infiltration, constitutes an \"immune-desert\" tumor displaying insensitivity to various immunotherapies. This study aims to explore therapeutic strategies for inducing tertiary lymphoid structure (TLS) formation within the glioma microenvironment (GME) to transition it from an immune-resistant to an activated state.</p><p><strong>Methods: </strong>TLS formation in GME was successfully induced by intracranial administration of Toll-like receptor (TLR) agonists (OK-432, TLR2/4/9 agonist) and glioma antigens (i.c. αTLR-mix). We employed staining analysis, antibody neutralization, single-cell RNA sequencing (scRNA-Seq), and BCR/TCR sequencing to investigate the underlying mechanisms of TLS formation and its role in anti-glioma immunity. Additionally, a preliminary translational clinical study was conducted.</p><p><strong>Results: </strong>TLS formation correlated with increased lymphocyte infiltration in GME and led to improved prognosis in glioma-bearing mice. In the study of TLS induction mechanisms, certain macrophages/microglia and Th17 displayed markers of \"LTo\" and \"LTi\" cells, respectively, interaction through LTα/β-LTβR promoted TLS induction. Post-TLS formation, CD4+ and CD8+ T cells but not CD19+ B cells contributed to anti-glioma immunity. Comparative analysis of B/T cells between brain and lymph node showed that brain B/T cells unveiled switch from naïve to mature, some B cells highlighted an enrichment of CSR-associated genes, V gene usage and clonotype bias were observed. In related clinical studies, i.c. αTLR-mix treatment exhibited tolerability, and chemokines/cytokines assay provided preliminary evidence supporting TLS formation in GME.</p><p><strong>Conclusion: </strong>TLS induction in GME enhanced anti-glioma immunity, improved the immune microenvironment, and controlled glioma growth, suggesting potential therapeutic avenues for treating glioma in the future.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/neuonc/noae167","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Glioma, characterized by limited lymphocytic infiltration, constitutes an "immune-desert" tumor displaying insensitivity to various immunotherapies. This study aims to explore therapeutic strategies for inducing tertiary lymphoid structure (TLS) formation within the glioma microenvironment (GME) to transition it from an immune-resistant to an activated state.

Methods: TLS formation in GME was successfully induced by intracranial administration of Toll-like receptor (TLR) agonists (OK-432, TLR2/4/9 agonist) and glioma antigens (i.c. αTLR-mix). We employed staining analysis, antibody neutralization, single-cell RNA sequencing (scRNA-Seq), and BCR/TCR sequencing to investigate the underlying mechanisms of TLS formation and its role in anti-glioma immunity. Additionally, a preliminary translational clinical study was conducted.

Results: TLS formation correlated with increased lymphocyte infiltration in GME and led to improved prognosis in glioma-bearing mice. In the study of TLS induction mechanisms, certain macrophages/microglia and Th17 displayed markers of "LTo" and "LTi" cells, respectively, interaction through LTα/β-LTβR promoted TLS induction. Post-TLS formation, CD4+ and CD8+ T cells but not CD19+ B cells contributed to anti-glioma immunity. Comparative analysis of B/T cells between brain and lymph node showed that brain B/T cells unveiled switch from naïve to mature, some B cells highlighted an enrichment of CSR-associated genes, V gene usage and clonotype bias were observed. In related clinical studies, i.c. αTLR-mix treatment exhibited tolerability, and chemokines/cytokines assay provided preliminary evidence supporting TLS formation in GME.

Conclusion: TLS induction in GME enhanced anti-glioma immunity, improved the immune microenvironment, and controlled glioma growth, suggesting potential therapeutic avenues for treating glioma in the future.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
TLR 激动剂可促进三级淋巴结构的形成,提高抗胶质瘤免疫力。
背景:胶质瘤以有限的淋巴细胞浸润为特征,是一种对各种免疫疗法不敏感的 "免疫荒漠 "肿瘤。本研究旨在探索在胶质瘤微环境(GME)中诱导三级淋巴结构(TLS)形成的治疗策略,使其从免疫抗性状态转变为活化状态:方法:通过颅内注射Toll样受体(TLR)激动剂(OK-432,TLR2/4/9激动剂)和胶质瘤抗原(i.c. αTLR-mix),成功诱导了胶质瘤微环境中三级淋巴结构的形成。我们采用染色分析、抗体中和、单细胞RNA测序(scRNA-Seq)和BCR/TCR测序来研究TLS形成的潜在机制及其在抗胶质瘤免疫中的作用。此外,还进行了一项初步的转化临床研究:结果:TLS的形成与GME中淋巴细胞浸润的增加相关,并能改善胶质瘤小鼠的预后。在TLS诱导机制的研究中,某些巨噬细胞/小胶质细胞和Th17分别显示出 "LTo "和 "LTi "细胞的标记,通过LTα/β-LTβR的相互作用促进了TLS的诱导。TLS形成后,CD4+和CD8+ T细胞而非CD19+ B细胞有助于抗胶质瘤免疫。脑部和淋巴结B/T细胞的比较分析表明,脑部B/T细胞揭示了从幼稚到成熟的转变,一些B细胞突出了CSR相关基因的富集,观察到了V基因使用和克隆型偏倚。在相关的临床研究中,静脉注射αTLR混合物治疗显示出耐受性,趋化因子/细胞因子检测提供了支持GME中TLS形成的初步证据:结论:在GME中诱导TLS可增强抗胶质瘤免疫力,改善免疫微环境,控制胶质瘤生长,为未来治疗胶质瘤提供了潜在的治疗途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Neuro-oncology
Neuro-oncology 医学-临床神经学
CiteScore
27.20
自引率
6.30%
发文量
1434
审稿时长
3-8 weeks
期刊介绍: Neuro-Oncology, the official journal of the Society for Neuro-Oncology, has been published monthly since January 2010. Affiliated with the Japan Society for Neuro-Oncology and the European Association of Neuro-Oncology, it is a global leader in the field. The journal is committed to swiftly disseminating high-quality information across all areas of neuro-oncology. It features peer-reviewed articles, reviews, symposia on various topics, abstracts from annual meetings, and updates from neuro-oncology societies worldwide.
期刊最新文献
Brain tumoroids: treatment prediction and drug development for brain tumors with fast, reproducible and easy-to-use personalized models Cognitive phenotypes: Unraveling the heterogeneity in cognitive dysfunction among patients with primary brain tumors receiving radiotherapy. EGFR and EGFRvIII coopt host defense pathways, promoting progression in glioblastoma. Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial. EDA2R reflects the acute brain response to cranial irradiation in liquid biopsies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1